Oncobix Co., Ltd. is a company that aims to develop innovative targeted therapies that meet the unmet needs of diseases that are difficult to treat effectively in modern medicine. Currently, we are developing targeted anti-cancer drugs such as lung cancer, liver cancer, lymphoma, and autoimmune diseases such as rheumatoid arthritis, Loops, psoriasis, and Shogren's syndrome, and we are planning and promoting further targeted drug development. We continue to discover pipelines that are likely to develop into global new drugs and strive to grow into new drug companies that specialize in developing them.
What is the Oncobix?
Outlines of Oncobix
Misson & Vision
Advenced Drug-Discovery TOFOP
Mutation in the kinase region of the epidermal growth factor receptor (EGFR) is found in some non-small cell lung cancer patients as a cause of cancer. The epidermal cell growth factor receptor kinase inhibitors for treating these egfr mutations include 1st generation gefitinib, erlotinib, 2nd generation afatinib, dacomitinib and 3rd generation osimertinib and Tagrisso.
However, using these inhibitors, most patients develop resistance to the previous generation of drugs within a year.
Among these resistances, the T790M variation in the epidermal growth factor receptor is observed up to 60%, and subsequent resistance to third-generation drugs reveals the mechanisms of C797S and C-MET.
Therefore, it is necessary to develop drugs to treat patients who are unable to use third-generation drugs due to T790S, C797S and C-MET resistance.
We have confirmed that OBX02-011 is not only effective in DEL19+T790M+C797S variation but also has excellent inhibitory effect on L858R+T790M+C797S through analysis at the level of KINASE ASSAY and cells. Comparing the inhibitory effect on mutated cells to the IC50 value, it was confirmed that they were superior to BRIGATINIB and OSIMERTINIB, which are already used as third and fourth-generation drugs.
In addition, OBX02-011 inhibitors were found to have high selectivity that worked little on normal cells and only on mutated cells. Therefore, it is expected to be quite competitive when it is newly launched in the existing anti-cancer drug market, which is struggling with side effects from low selectivity for cancer cells. Based on the upper data, we will provide a fourth-generation drug that is less resistant and displays more selectivity.
The OBX02-011 compound is found to be effective in patients who have developed resistance to the third-generation treatment of non-small cell lung cancer.
The effect of inhibiting representative mutations (del19+t790m+c191s, l858r+t790m+c797s) that are expressed after treatment of previous generation therapeutic agents has been verified through numerical results and tissue experiments.
Above all, the OBX02-011 compound is a small molecule that easily melts in water and has little effect on normal WAIDD-type cells other than cancer cells, so it is expected to overcome the problems experienced in the use of existing anticancer drugs.